Photodynamic therapy with and without adjunctive intravitreal triamcinolone acetonide: A retrospective comparative study

Ophthalmic Surgery Lasers and Imaging

Volumn 40, Issue 6, 2009, Pages 561-569

  Chan, Annie ^a   Blumenkranz, Mark S ^a   Wu, Kathy H C ^a   Wang, Gloria ^a   Berker, Nilufer ^a   Parast, Layla M ^b   Sanislo, Steven R ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; TRIAMCINOLONE ACETONIDE; VERTEPORFIN;

ADJUVANT THERAPY; ADVERSE OUTCOME; AGED; ANGIOGRAPHY; ARTICLE; CATARACT; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOPHTHALMITIS; FEMALE; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETREATMENT; RETROSPECTIVE STUDY; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS HEMORRHAGE;

AGED; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY; VITREOUS BODY;

EID: 72249101575     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20091030-05     Document Type: Article

References (32)

1. Chakravarthy U. Age related macular degeneration. BMJ. 2006;333:869-870.
2. Rahmani B, Tielsch JM, Katz J, et al. The cause-specific prevalence of visual impairment in an urban population: the Baltimore Eye Survey. Ophthalmology. 1996;103:1721-1726. (Pubitemid 26403720)
3. Wang JJ, Foran S, Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2000;28:268-273.
4. Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology. 2007;114:92-98. (Pubitemid 46014292)
5. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol. 2003;48:257-293. (Pubitemid 36553096)
6. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol. 1999;117:1329-1345.
7. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 2001;131:541-560. (Pubitemid 32427660)
8. Folkman J, Ingber DE. Angiostatic steroids: method of discovery and mechanism of action. Ann Surg. 1987;206:374-383. (Pubitemid 17159712)
9. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309-315. (Pubitemid 28131129)
10. Oh H, Takagi H, Takagi C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891-1898. (Pubitemid 29365148)
11. Penfold PL, Wen L, Madigan MC, Gillies MC, King NJ, Provis JM. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line: implications for macular degeneration. Clin Exp Immunol. 2000;121:458-465. (Pubitemid 30671267)
12. Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin Experiment Ophthalmol. 2001;29:188-192. (Pubitemid 32618988)
13. Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol. 2002;240:42-48. (Pubitemid 36075572)
14. Wilson CA, Berkowitz BA, Sato Y, Ando N, Handa JT, de Juan E Jr. Treatment with intravitreal steroid reduces blood-retinal barrier breakdown due to retinal photocoagulation. Arch Ophthalmol. 1992;110:1155-1159.
15. Zarbin M. Should corticosteroids be considered as part of the standard care with photodynamic therapy? Arch Ophthalmol. 2006;124:563-571.
16. Kato A, Kimura H, Okabe K, et al. Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide. Retina. 2005;25:503-509. (Pubitemid 40791890)
17. Obata R, Iriyama A, Inoue Y, Takahashi H, Tamaki Y, Yanagi Y. Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro. Br J Ophthalmol. 2007;91:100-104. (Pubitemid 46094019)
18. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2003;110:1517-1525. (Pubitemid 36962483)
19. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization. Retina. 2005;25: 685-690. (Pubitemid 41254536)
20. Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology. 2006;113:2243-2250. (Pubitemid 44838921)
21. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006;113:14-22. (Pubitemid 43021722)
22. Ergun E, Maar N, Ansari-Shahrezaei S, et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am J Ophthalmol. 2006;142:10-16. (Pubitemid 43946797)
23. Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br J Ophthalmol. 2004;88:344-347. (Pubitemid 38333711)
24. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2006;141:638-645.
25. Ruiz-Moreno JM, Montero JA, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 2-year outcome. Retina. 2007;27:458-461. (Pubitemid 46624286)
26. Gilson MM, Bressler NM, Jabs DA, Solomon SD, Thorne JE, Wilson DJ. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology. 2007;114:1713-1721.
27. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431. (Pubitemid 44511557)
28. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444. (Pubitemid 44511558)
29. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143:566-583.
30. Hopley C, Salkeld G, Mitchell P. Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol. 2004;88:982-987. (Pubitemid 39013134)
31. Smiddy WE. Relative cost of a line of vision in age-related macular degeneration. Ophthalmology. 2007;114:847-854.
32. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007;27:133-140. (Pubitemid 46245638)